|
テルイ ヤスヒト
TERUI Yasuhito
照井 康仁 所属 埼玉医科大学 医学部 血液内科 職種 教授 |
|
| 論文種別 | 学術雑誌(原著) |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis |
| 掲載誌名 | 正式名:Int J Hematol ISSNコード:18653774 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 111,103-111頁 |
| 著者・共著者 | Suzuki, K., Tsukada, N., Nishimura, N., Nagata, Y., Okazuka, K., Mishima, Y., Yokoyama, M., Nishiwaki, K., Ishida, T., Yano, S., Terui, Y. |
| 発行年月 | 2020 |
| 概要 | The combination of bortezomib, lenalidomide, and dexamethasone (VRD) is used as induction treatment in multiple myeloma; however, the optimum schedule for this regimen remains controversial. In this retrospective study, we compared the efficacy and tolerability of twice-weekly VRD (twVRD) and modified VRD-lite in transplant-eligible myeloma patients. Fifty-five patients (median age 61 years) were included; 22 received twVRD (bortezomib [1.3 mg/m |
| DOI | 10.1007/s12185-019-02764-1 |
| 文献番号 | 31673952 |